1/48
Looks like no tags are added yet.
what is the role of mitotic spindles
partitioning of DNA into 2 daughter cells
antimitotic: vincristine, vinblastine, vinorelbine
interferes with microtubule function by binding to tubulin
IV, fatal with other routes
M phase
vincristine
TX:
ALL
Hodgkins and non Hodgkins
S/E:
- dose limiting neurotoxicity with peripheral neuropathy
- alopecia
- mild myelosuppression
what is the R-CHOP therapy for non-Hodgkins lymphoma
Rituximab
Cyclophosphamide
doxorubicin Hcl
Vincristine
Prednisone
what is the ABVD therapy for Hodgkins lymphoma
Doxorubicin
Bleomycin
Vincristine
Dacarbazine
Prednisone
vinblastine
TX:
NH and H lymphoma
S/E: myelosuppression and neurotoxicity
what combo is used for testicular cancer
vinblastine
bleomycin
cisplatin
vinorelbine
TX
advanced non small cell
S/E: granulocytopenia
Anti microtubules
G2/M phase
promote polymerization and prevent disassembly that leads to accumulation and cell death
Anti microtubules: paclitaxel & docetaxel
S/E: neutropenia, leukopenia
patients treated with paclitaxel should be premedicated with
dexamethasone
diphenhydramine
topoisomerase inhibitors I
irinotecan
topotecan
S phase topo I
IV
platinum
cisplatin
carboplatin
oxaliplatin
platinum Moa
cross link DNA and interfere with DNA synthesis and cell replication like alkylating agents
G1 and S phase
what tumors are cisplatin targeting
solid
cisplatin
dose limiting nephrotoxicity
neurotoxicity
ototoxicity
infusion rxn
carboplatin
pts should be vigorously hydrated
neuro and ototoxicity
oxaliplatin
tx: colorectal cancer
neuro and liver toxicity
infusion rxn
oncogenes are developed from normal ___
proto-oncogenes
oncogenes turn healthy cells into ___
cancer cells
proto-oncogenes
important in normal cellular function
genetic alterations in proto-oncogenes
pt mutation
chromosomal rearrangement
gene amplification
oncogenes examples
EGFR:
HER2, 3, 4
monoclonal antibodies
targeted therapy
created from B lymphocytes from immunized mice infused with immoral b lymphocyte tumor cells
trastuzumab
moa: overexpression of HER2 and blocks downstream signaling pathway
breast
gastric
S/E: pulmonary toxicity, HF
rituximab
moa: antagonist against CD20 antigen on malignant B lymphocytes in NH lymphoma
R-CHOP
S/E: hypotension, bronchospasm, angioedema
infuse slowly
admin with APAP, Benadryl, and corticosteroids
what was the first monoclonal used for cancer TX
rituximab
bevacizumab
moa: antiangiogenesis; stops VEGF
TX: colorectal cancer
used with 5-FU
S/E: HTN, GI, proteinuria, bleeding
cetuximab & panitumumab
moa: KRAS on EGFR
rash is positive TX sign
IV
most serious S/E for bleomycin
pulmonary toxicity
FOLFIRINOX TX for GI tumors
Leucovorin
5-FU
Irinotecan
Oxaliplatin
which of the following drugs is not apart of FLOFIRINOX combo
a/ sunitinib
b/ leucovorin
c/ irinotecan
d/ 5-FU
e/ oxaliplatin
sunitinib
a 32 yr old male suffering from a cold started taking several different OTC cold/flu medications to relieve symptoms. she was later admitted to the hospital with elevated levels of N-acteyl-p- benzoquinone. what toxicity is of potential serious importance?
hepatotoxicity
a patient is preparing for pre-op analgesia and the anesthesiologist needs an adjuvant anesthesia that has rapid onset and short duration and 100x more potent than morphine. what is the agent
fentanyl
treatment for acute and chronic lymphocytic leukemia, NH lymphoma, breast, ovarian cancer and produced nephrotoxic and urotoxic metabolite acrolein. what is the agent
cyclophosphamide
a patient diagnosed with pancreatic cancer was administered agent IV. he begins to develop myelosuppression and hepatic toxicity. what drug is he taking
gemcitabine
a physician prescribed an immune checkpoint inhibitor to treat metastatic melanoma and the patient developed autoimmune toxicity. what drug is he taking
a. ipilimumab
b/ olaparib
c. venetoclax
d/ thalidomide
e/ lapatinib
a. ipilimumab
a patient was prescribed proteasome inhibitor and developed thrombocytopenia, fatigue and peripheral neuropathy. what drug is responsible
a/ bortezomib
b/ rituximab
c/ ofatmumab
d/ sorafenib
e/ pazopanib
a/ bortezomib
which of the following is not a major problem with drug resistance in cancer chemo
a/ activation of cancer drugs
b/ increased DNA repair
c/ changes in targeted enzymes
d/ decreased drug accumultation
e/ decreased activation of prodrugs
a/ activation of cancer drugs
this drug is a pyrimidine analog antimetabolite agent from the cytotoxic drug class that substitutes for the normal uracil in RNA so inhibits protein synthesis and the cells can't proliferate
a/ 5-FU
b/ cyclophosphamide
c/ 6- mercaptopurine
d/ premetrexate
e/ methotrexate
a/ 5-FU
a patient with testicular and H lymphoma cancer presented to the ER experiencing pulmonary toxicity and mucocutaneous rxn. what drug is respsonsible
a/ bleomycin
b/ doxorubicin
c/ cyclophosphamide
d/ fulvestrant
e/ anastrazole
a/ bleomycin
Bill developed thrombocytopenia, peripheral neuropathy, and fatigue. during relapse therapy for multiple melanoma. what drug is repsonsible
a/ bortezomib
b/ imatinib
c/ carmustine
d/ panitumumab
e/ gemtuzumab
a/ bortezomib
this patient developed advance NSCLC that is resistant to other EGFR kinase inhibitors. which kinase inhibitor is best suited for treatment
a/ osimertinib
b/ certuximab
c/ lapatinib
d/ neratinib
e/ trastuzumab
a/ osimertinib
a patient developed advanced ER +, HER2 - breast cancer and received combo therapy fulvestrant. what cyclin-dependent kinase 4/6 inhibitor is used
a/ palociclib
b/ ibrutinib
c/ imatinib
d/ nilotinib
e/ trastuzumab
a/ palociclib
a patient developed metastatic melanoma and was treated with a single agent. what is the agent
a/ ipilimumab
b/ rituximab
c/ daratumumab
d/ dinutuximab
e/ ofatumumab
a/ ipilimumab
a patient with HER2 amplified trastuzumab refractory breast cancer is looking for an optional therapy. what is best option
a/ lapatinib
b/ imatinib
c/ erlotinib
d/ sorafenib
e/ dasatinib
a/ lapatinib
combo therapy with lenalidomide or bortezmob to treat multiple myeloma and started to experience infusion rxn, peripheral neuropathy, and URT infection. what agent is responsible
a/ daratumumab
b/ elotuzumab
c/ blinatumomab
d/ dinutuximab
e/ venetoclax
a/ daratumumab
a group of patients taking intracellular kinase had 50-70% fatigue, 40-60% developed hypothyroidism, what agent is responsible
a/ sunitinib
b/ ramucirumab
c/ vandetanib
d/ labetalol
e/ nilotinib
a/ sunitinib
a patient developed resistance to a previous treatment for CML and developed thrombosis, hepatotoxicity and pancreatitis. what agent is it
a/ ponatinib
b/ bosutinib
c/ alectinib
d/ idelalisib
e/ everolimus
a/ ponatinib